Gaboxadol
Gaboxadol is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target gamma-aminobutyric acid receptor subunit alpha-2, gamma-aminobutyric acid receptor subunit alpha-3, gamma-aminobutyric acid receptor subunit rho-2, gamma-aminobutyric acid receptor subunit rho-3, gamma-aminobutyric acid receptor subunit alpha-6, gamma-aminobutyric acid receptor subunit alpha-1, gamma-aminobutyric acid receptor subunit rho-1, gamma-aminobutyric acid receptor subunit alpha-4, gamma-aminobutyric acid receptor subunit delta, and gamma-aminobutyric acid receptor subunit alpha-5.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
19 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sleep initiation and maintenance disorders | D007319 | F51.01 | — | 2 | 13 | — | — | 15 | |
| Angelman syndrome | D017204 | Orphanet_72 | Q93.51 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fragile x syndrome | D005600 | Q99.2 | — | 2 | — | — | — | 2 | |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | GABOXADOL |
| INN | gaboxadol |
| Description | 4,5,6,7-Tetrahydroisoxazolo(5,4-c)pyridin-3-ol is an oxazole. |
| Classification | Small molecule |
| Drug class | analgesics (mixed opiate receptor agonists/antagonists); gabamimetics |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Oc1noc2c1CCNC2 |
Identifiers
| PDB | — |
| CAS-ID | 64603-91-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL312443 |
| ChEBI ID | 34373 |
| PubChem CID | 3448 |
| DrugBank | DB06554 |
| UNII ID | K1M5RVL18S (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
GABRA2
GABRA2
GABRA3
GABRA3
GABRR2
GABRR2
GABRR3
GABRR3
GABRA6
GABRA6
GABRA1
GABRA1
GABRR1
GABRR1
GABRA4
GABRA4
GABRD
GABRD
GABRA5
GABRA5
Organism
Homo sapiens
Gene name
GABRA2
Gene synonyms
NCBI Gene ID
Protein name
gamma-aminobutyric acid receptor subunit alpha-2
Protein synonyms
GABA(A) receptor subunit alpha-2, gamma-aminobutyric acid type A receptor alpha2 subunit
Uniprot ID
Mouse ortholog
Gabra2 (14395)
gamma-aminobutyric acid receptor subunit alpha-2 (P26048)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 884 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more